Organon & Co. (NYSE:OGN) SVP Lynette Holzbaur Buys 26,448 Shares

Organon & Co. (NYSE:OGN) SVP Lynette Holzbaur bought 26,448 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The shares were bought at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the transaction, the senior vice president directly owned 52,851 shares in the company, valued at $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Organon & Co. Stock Performance

OGN opened at $13.35 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.23 and a debt-to-equity ratio of 9.47. The company’s fifty day moving average price is $8.00 and its two-hundred day moving average price is $7.82. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.44. The company has a market cap of $3.50 billion, a price-to-earnings ratio of 14.35, a PEG ratio of 1.24 and a beta of 1.57.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the company posted $1.02 EPS. The business’s quarterly revenue was down 3.5% on a year-over-year basis. On average, analysts expect that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be issued a dividend of $0.02 per share. The ex-dividend date is Monday, May 11th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s dividend payout ratio is presently 8.60%.

Institutional Trading of Organon & Co.

Several institutional investors have recently made changes to their positions in OGN. Royal Bank of Canada grew its stake in shares of Organon & Co. by 53.4% in the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock worth $5,374,000 after acquiring an additional 125,648 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Organon & Co. by 126.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after acquiring an additional 801,307 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Organon & Co. by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock worth $15,530,000 after acquiring an additional 26,640 shares in the last quarter. Focus Partners Wealth grew its stake in shares of Organon & Co. by 33.2% in the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock worth $832,000 after acquiring an additional 13,925 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Organon & Co. in the 2nd quarter worth $107,000. Institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

OGN has been the topic of several research reports. Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Barclays upped their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and upped their price objective for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. BNP Paribas Exane restated a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Zacks Research upgraded shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Four equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and an average target price of $11.40.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.